Patents by Inventor Gianni Motta

Gianni Motta has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8580962
    Abstract: The invention is directed to methods of using antagonists selective for the metabotropic mGlu5 receptor to treat conditions of neuromuscular dysfunction of the lower urinary tract in a mammal. Provided are methods of treating a mammal suffering from a condition of neuromuscular dysfunction of the lower urinary tract by administering a selective mGlu5 antagonist. The selective mGlu5 antagonist may be administered alone or in combination with one or more additional therapeutic agents for treating such a condition. Also provided are methods of identifying selective mGlu5 antagonists that are useful for treating neuromuscular dysfunction of the lower urinary tract in a mammal. Methods for treating migraine and gastroesophageal reflux disease (GERD) using selective mGlu5 antagonists are also disclosed.
    Type: Grant
    Filed: July 11, 2011
    Date of Patent: November 12, 2013
    Assignee: Recordati Ireland Ltd.
    Inventors: Amedeo Leonardi, Gianni Motta, Carlo Riva, Luciano Guarneri, Davide Graziani, Carlo De Toma, Katia Dimitrova Karamfilova
  • Patent number: 8518916
    Abstract: This invention relates to novel heterocyclic compounds having selective affinity for the mGlu5 subtype of metabotropic receptors, pharmaceutical compositions thereof and uses for such compounds and compositions in the treatment of lower urinary tract disorders, such as neuromuscular dysfunction of the lower urinary tract, and in the treatment of migraine and gastroesophagael reflux disease (GERD).
    Type: Grant
    Filed: August 4, 2008
    Date of Patent: August 27, 2013
    Assignee: Recordati Ireland Limited
    Inventors: Amedeo Leonardi, Gianni Motta, Carlo Riva, Elena Poggesi, Davide Graziani, Matteo Longhi
  • Publication number: 20120059015
    Abstract: The invention is directed to methods of using antagonists selective for the metabotropic mGlu5 receptor to treat conditions of neuromuscular dysfunction of the lower urinary tract in a mammal. Provided are methods of treating a mammal suffering from a condition of neuromuscular dysfunction of the lower urinary tract by administering a selective mGlu5 antagonist. The selective mGlu5 antagonist may be administered alone or in combination with one or more additional therapeutic agents for treating such a condition. Also provided are methods of identifying selective mGlu5 antagonists that are useful for treating neuromuscular dysfunction of the lower urinary tract in a mammal. Methods for treating migraine and gastroesophageal reflux disease (GERD) using selective mGlu5 antagonists are also disclosed.
    Type: Application
    Filed: July 11, 2011
    Publication date: March 8, 2012
    Applicant: Recordati Ireland Ltd.
    Inventors: Amedeo Leonardi, Gianni Motta, Carlo Riva, Luciano Guarneri, Davide Graziani, Carlo De Toma, Katia Dimitrova Karamfilova
  • Publication number: 20120028931
    Abstract: Compounds I (R1 is an optionally substituted C1-C13 heteromonocyclic, heterobicyclic or heterotricyclic group containing from 1 to 5 heteroatoms selected from N, O and S; R2 is H, an optionally substituted monocyclic aromatic group, or a C1-C5 heteroaromatic group containing from 1 to 4 heteroatoms selected from N, O and S; R3 is an optionally substituted C1-C13 heteromonocyclic, heterobicyclic or heterotricyclic group containing from 1 to 5 heteroatoms selected from N, O and S; an optionally substituted mono-, bi- or tricyclic C6-C14 aryl group, an optionally substituted C3-C6 cycloalkyl group, or an optionally substituted C3-C6 cycloalkenyl group; each R4, independently for each position capable of substitution, is H or C1-C6 alkyl; R5 is H, halogen or C1-C6 alkyl; m is 0, 1 or 2; n is 0, 1 or 2; p is 0, 1, 2, 3, 4, 5, or 6; and is an optional double bond) and their enantiomers, diastereomers, N-oxides and pharmaceutically acceptable salts, and pharmaceutical compositions containing them, are useful f
    Type: Application
    Filed: September 14, 2010
    Publication date: February 2, 2012
    Applicant: RECORDATI IRELAND LIMITED
    Inventors: Amedeo Leonardi, Carlo Riva, Luciano Guarneri, Davide Graziani, Fabio Marinoni, Gianni Motta, Ilaria Bettinelli
  • Publication number: 20100317630
    Abstract: The invention is directed to methods of using antagonists selective for the metabotropic mGlu5 receptor to treat conditions of neuromuscular dysfunction of the lower urinary tract in a mammal. Provided are methods of treating a mammal suffering from a condition of neuromuscular dysfunction of the lower urinary tract by administering a selective mGlu5 antagonist. The selective mGlu5 antagonist may be administered alone or in combination with one or more additional therapeutic agents for treating such a condition. Also provided are methods of identifying selective mGlu5 antagonists that are useful for treating neuromuscular dysfunction of the lower urinary tract in a mammal. Methods for treating migraine and gastroesophageal reflux disease (GERD) using selective mGlu5 antagonists are also disclosed.
    Type: Application
    Filed: February 4, 2010
    Publication date: December 16, 2010
    Applicant: RECORDATI IRELAND LIMITED
    Inventors: Amedeo Leonardi, Gianni Motta, Carlo Riva, Elena Poggesi, Davide Graziani
  • Patent number: 7820701
    Abstract: The invention provides a substantially pure amorphous lercanidipine hydrochloride having a purity of at least 95% pure, preferably at least about 97% pure, more preferably at least about 99% pure, and still more preferably at least about 99.5% pure. The invention further relates to methods of preparing substantially pure amorphous lercanidipine, as well as methods of providing rapid relief from hypertension by administering the substantially pure amorphous lercanidipine hydrochloride of the present invention to a patient in need of such treatment.
    Type: Grant
    Filed: February 27, 2006
    Date of Patent: October 26, 2010
    Assignee: Recordati Ireland Limited
    Inventors: Amedeo Leonardi, Gianni Motta, Fabio Berlati
  • Patent number: 7683179
    Abstract: The present invention relates to new addition salts of lercanidipine comprising lercanidipine and an acid counterion wherein the acid counterion is selected from the group consisting of: (i) inorganic acids, (ii) sulfonic acids, (iii) monocarboxylic acids, (iv) dicarboxylic acids, (v) tricarboxylic acids, and (vi) aromatic sulfonimides, with the proviso that said acid counterion is not hydrochloric acid.
    Type: Grant
    Filed: August 24, 2005
    Date of Patent: March 23, 2010
    Assignee: Recordati Ireland Limited
    Inventors: Amedeo Leonardi, Gianni Motta, Markus von Raumer
  • Publication number: 20090042841
    Abstract: This invention relates to novel heterocyclic compounds having selective affinity for the mGlu5 subtype of metabotropic receptors, pharmaceutical compositions thereof and uses for such compounds and compositions in the treatment of lower urinary tract disorders, such as neuromuscular dysfunction of the lower urinary tract, and in the treatment of migraine and gastroesophagael reflux disease (GERD).
    Type: Application
    Filed: August 4, 2008
    Publication date: February 12, 2009
    Applicant: Recordati Ireland Limited
    Inventors: Amedeo Leonardi, Gianni Motta, Carlo Riva, Elena Poggesi, Davide Graziani, Matteo Longhi
  • Publication number: 20070270436
    Abstract: Described are novel amino- and iminoalkyl piperazines having affinity for serotonergic receptors and pharmacological compositions thereof. These compounds and their isomers, including optical isomers, enantiomers, diastereomers, N-oxides, polymorphs, hydrates, solvates and pharmaceutically acceptable salts are useful in the treatment of patients with neuromuscular dysfunction of the lower urinary tract and CNS diseases and/or disorders associated with 5-HT1A receptor dysfunction.
    Type: Application
    Filed: May 21, 2007
    Publication date: November 22, 2007
    Applicant: Recordati Ireland Limited
    Inventors: Amedeo Leonardi, Gianni Motta, Carlo Riva, Luciano Guarneri
  • Publication number: 20070185129
    Abstract: The invention relates to novel addition salts of N-{3-[4-(2-Methoxyphenyl)-1-piperazinyl]propyl}-7-oxo-5-trifluoromethyl-7H-thieno[3,2-b]pyran-3-carboxamide, comprising N-{3-[4-(2-Methoxyphenyl)-1-piperazinyl]propyl}-7-oxo-5-trifluoromethyl-7H-thieno[3,2-b]pyran-3-carboxamide and an acid counterion wherein the acid counterion is selected from the group consisting of: (i) inorganic acids and (ii) sulfonic acids.
    Type: Application
    Filed: February 5, 2007
    Publication date: August 9, 2007
    Applicant: Recordati Ireland Limited
    Inventors: Amedeo Leonardi, Gianni Motta
  • Publication number: 20060211742
    Abstract: The invention provides a substantially pure amorphous lercanidipine hydrochloride having a purity of at least 95% pure, preferably at least about 97% pure, more preferably at least about 99% pure, and still more preferably at least about 99.5% pure. The invention further relates to methods of preparing substantially pure amorphous lercanidipine, as well as methods of providing rapid relief from hypertension by administering the substantially pure amorphous lercanidipine hydrochloride of the present invention to a patient in need of such treatment.
    Type: Application
    Filed: February 27, 2006
    Publication date: September 21, 2006
    Applicant: Recordati Ireland Limited
    Inventors: Amedeo Leonardi, Gianni Motta, Fabio Berlati
  • Publication number: 20060199849
    Abstract: The invention provides substantially pure lercanidipine free base, having a purity of at least 95%, preferably at least 97%, more preferably at least 99%, and still more preferably at least 99.5%. The lercanidipine free base of the present invention is formed as an amorphous solid that is easily handled and particularly well suited to the formulation of pharmaceutical compositions.
    Type: Application
    Filed: February 27, 2006
    Publication date: September 7, 2006
    Applicant: Recordati Ireland Limited
    Inventors: Fabio Berlati, Amedeo Leonardi, Gianni Motta, Ilaria Candiani, Francesco Corcella
  • Publication number: 20060148821
    Abstract: N,N-Disubstituted diazocycloalkanes of the formula I (R1=halogen, R2=(C3-C8)-cycloalkyl, R3=(C1-C4)-alkoxy or (C1-C4)-haloalkoxy group, m is 1 or 2 and n is 1 or 2, have affinity for serotonergic receptors. These compounds and their enantiomers, diastereoisomers, N-oxides, polymorphs, solvates and pharmaceutically acceptable salts are useful in the treatment of patients with neuromuscular dysfunction of the lower urinary tract and diseases related to 5-HT1A receptor.
    Type: Application
    Filed: February 27, 2006
    Publication date: July 6, 2006
    Applicant: Recordati S.A.
    Inventors: Amedeo Leonardi, Gianni Motta, Carlo Riva, Rodolfo Testa
  • Patent number: 7071197
    Abstract: N,N-Disubstituted diazocycloalkanes of the formula I (R1=halogen, R2=(C3–C8)-cycloalkyl, R3=(C1–C4)-alkoxy or (C1–C4)-haloalkoxy group, m is 1 or 2 and n is 1 or 2, have affinity for serotonergic receptors. These compounds and their enantiomers, diastereoisomers, N-oxides, polymorphs, solvates and pharmaceutically acceptable salts are useful in the treatment of patients with neuromuscular dysfunction of the lower urinary tract and diseases related to 5-HT1A receptor.
    Type: Grant
    Filed: June 16, 2003
    Date of Patent: July 4, 2006
    Assignee: Recordati S.A.
    Inventors: Amedeo Leonardi, Gianni Motta, Carlo Riva, Rodolfo Testa
  • Publication number: 20060047125
    Abstract: The present invention relates to new addition salts of lercanidipine comprising lercanidipine and an acid counterion wherein the acid counterion is selected from the group consisting of: (i) inorganic acids, (ii) sulfonic acids, (iii) monocarboxylic acids, (iv) dicarboxylic acids, (v) tricarboxylic acids, and (vi) aromatic sulfonimides, with the proviso that said acid counterion is not hydrochloric acid.
    Type: Application
    Filed: August 24, 2005
    Publication date: March 2, 2006
    Applicant: Recordati Ireland Limited
    Inventors: Amedeo Leonardi, Gianni Motta, Markus von Raumer
  • Patent number: 6953800
    Abstract: Described is the use in the treatment of either male or female sexual dysfunction of selective antagonists of the ?1B-adrenergic receptor and the pharmaceutical compositions containing them as compounds capable of helping the sexual act avoiding at the same time excessive side effects due to acute hypotension.
    Type: Grant
    Filed: August 22, 2001
    Date of Patent: October 11, 2005
    Assignees: Recordati S.A. Chemical, Pharmaceutical Company
    Inventors: Amedeo Leonardi, Gianni Motta, Rodolfo Testa, Giorgio Sironi
  • Patent number: 6894052
    Abstract: Disclosed herein are novel compounds and methods for the treatment of disorders of the lower urinary tract. The novel compounds are diarylalkylpiperazine derivatives. The methods comprise the administration of the novel compounds of the invention, and other compounds that bind to 5HT1A receptors, for treating disorders of the lower urinary tract.
    Type: Grant
    Filed: July 31, 1998
    Date of Patent: May 17, 2005
    Assignee: Recordati S.A. Chemical and Pharmaceutical Company
    Inventors: Amedeo Leonardi, Gianni Motta, Carlo Riva, Rodolfo Testa
  • Publication number: 20040072839
    Abstract: Described are novel 1-phenylalkylpiperazines having affinity for serotonergic receptors. These compounds and their enantiomers, diastereoisomers, N-piperazine oxides, polymorphs, solvates and pharmaceutically acceptable salts are useful in the treatment of patients with neuromuscular dysfunction of the lower urinary tract and diseases related to 5-HT1A receptor activity. Also described are the preparation of the compounds and the pharmaceutical compositions containing them.
    Type: Application
    Filed: June 16, 2003
    Publication date: April 15, 2004
    Inventors: Amedeo Leonardi, Gianni Motta, Carlo Riva, Elena Poggesi
  • Publication number: 20040072822
    Abstract: N,N-Disubstituted diazocycloalkanes of the formula I 1
    Type: Application
    Filed: June 16, 2003
    Publication date: April 15, 2004
    Inventors: Amedeo Leonardi, Gianni Motta, Carlo Riva, Rodolfo Testa
  • Publication number: 20040058962
    Abstract: Described are novel substituted phenylalkylamines and pyridylalkylamines having affinity for serotonergic receptors. These compounds and their enantiomers, diastereoisomers, N-oxides, polymorphs, solvates and pharmaceutically acceptable salts are useful in the treatment of patients with neuromuscular dysfunction of the lower urinary tract and diseases related to 5-HT1A receptor. Also described are the preparation of the compounds and the pharmaceutical compositions containing them.
    Type: Application
    Filed: June 16, 2003
    Publication date: March 25, 2004
    Inventors: Amedeo Leonardi, Gianni Motta, Carlo Riva, Luciano Guarneri